Skip to main content

Kepler Capital Sticks to Its Hold Rating for Grifols SA (GRFS)

TipRanks - Sat Jul 2, 8:40PM CDT
Kepler Capital analyst Dariusz Ubik maintained a Hold rating on Grifols SA (GRFSResearch Report) on July 1 and set a price target of EUR22.90. The companys shares closed last Friday at $12.49.

According to TipRanks.com, Ubik is ranked #5991 out of 7906 analysts.

Currently, the analyst consensus on Grifols SA is a Moderate Buy with an average price target of $22.68.

See Insiders’ Hot Stocks on TipRanks >> Based on Grifols SAs latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.35 billion and net profit of $137 million. In comparison, last year the company earned revenue of $1.38 billion and had a net profit of $31.87 million. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain. Read More on GRFS: